Literature DB >> 16023876

Diagnosis and treatment of acromegaly.

Laurence Katznelson1.   

Abstract

Acromegaly is an insidious disease that occurs, in the majority of cases, as a result of a pituitary adenoma that hypersecretes growth hormone (GH). The clinical consequences of acromegaly are a function of excess GH secretion and mass effect of the pituitary tumor. The involvement of multiple organ systems may lead to significant morbidity and mortality, prompting the need for rapid and accurate disease recognition and treatment. This brief review will describe current recommendations for management of this uncommon, but debilitating, endocrine disorder.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16023876     DOI: 10.1016/j.ghir.2005.06.007

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  5 in total

1.  Efficacy and safety of CyberKnife radiosurgery for acromegaly.

Authors:  Brian K Roberts; Daniel L Ouyang; Shivanand P Lad; Steven D Chang; Griffith R Harsh; John R Adler; Scott G Soltys; Iris C Gibbs; Lynn Remedios; Laurence Katznelson
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

2.  Clinical features and therapeutic outcomes of acromegaly during the recent 10 years in a single institution in Japan.

Authors:  Izumi Fukuda; Naomi Hizuka; Toko Muraoka; Makiko Kurimoto; Yu Yamakado; Kazue Takano; Atsuhiro Ichihara
Journal:  Pituitary       Date:  2014-02       Impact factor: 4.107

Review 3.  [Treatment of pituitary gland hyperfunction: from acromegaly to prolactinoma].

Authors:  A Schäffler
Journal:  Internist (Berl)       Date:  2006-12       Impact factor: 0.743

4.  Daily life reflections of acromegaly guidelines.

Authors:  T Apaydin; H M Ozkaya; F E Keskin; O A Haliloglu; K Karababa; S Erdem; P Kadioglu
Journal:  J Endocrinol Invest       Date:  2016-10-20       Impact factor: 4.256

5.  Decrease in growth hormone and insulin-like growth factor (IGF)-1 release and amelioration of acromegaly features after rosiglitazone treatment of type 2 diabetes mellitus a patient with acromegaly.

Authors:  Marina Gradiser; Martina Matovinovic; Milan Vrkljan
Journal:  Croat Med J       Date:  2007-02       Impact factor: 1.351

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.